WS #16229
Biotech and defense-tech stocks are seeing specific catalysts, with Ouster reporting its lidar systems completing over 1,400 missions in Ukraine for Forterra autonomous vehicles. In pharma, Unicycive Therapeutics received FDA acceptance for its NDA resubmission, and Roivant Sciences reported that Brepocitinib met all Phase 3 endpoints for uveitis. These developments provide idiosyncratic upside for small and mid-cap names, distinct from the broader macro trends.
Biotech & FDA Catalysts
Biotech and defense-tech stocks are seeing specific catalysts, with Ouster reporting its lidar systems completing over 1,400 missions in Ukraine for Forterra autonomous vehicles. In pharma, Unicycive Therapeutics received FDA acceptance for its NDA resubmission, and Roivant Sciences reported that Brepocitinib met all Phase 3 endpoints for uveitis. These developments provide idiosyncratic upside for small and mid-cap names, distinct from the broader macro trends.